A Clarence biotechnology firm is expanding its cannabis subsidiary with an eye toward participating in the medical marijuana program here in New York and elsewhere.
Botanical Genetics LLC , a wholly-owned subsidiary of 22nd Century Group Inc. (NYSE MKT: XXII), will focus on developing proprietary cannabis strains for medical applications, and developing very low THC industrial hemp that may be legally grown in the U.S. and around the world as a commercial agricultural crop.
It’s the next step…
A Clarence biotechnology firm is expanding its cannabis subsidiary with an eye toward participating in the medical marijuana program here in New York and elsewhere.
Botanical Genetics LLC , a wholly-owned subsidiary of 22nd Century Group Inc. (NYSE MKT: XXII), will focus on developing proprietary cannabis strains for medical applications, and developing very low THC industrial hemp that may be legally grown in the U.S. and around the world as a commercial agricultural crop.
It’s the next step…